Public data, as of October 2026
The Data Hub has no reported emissions for this company yet, so there is no footprint to summarize.
Near-term status: Commitment to Set Targets. Net-zero status: no net-zero target on record.
Scope 3 appears once a full disclosure is matched.
A peer comparison appears once sector peers report their emissions.
No voluntary retirement names this company as beneficiary yet.
tCO₂e, GHG Protocol scopes
Peers: companies in the SBTi industry "Pharmaceuticals, Biotechnology and Life Sciences", by Scope 3 share of the latest reported footprint.
Claiming is free. Your team can correct data, add newer disclosures and list reduction projects from your value chain, so that customers and suppliers can co-fund them.
No reported emissions for this company yet
Carbon3 compiles emissions from published sustainability reports and normalizes them to the GHG Protocol scopes. This company has not been covered yet, or has not published figures that could be read reliably.
Scope 3 categories are not itemized yet
Categories appear once a published disclosure splits Scope 3 into the GHG Protocol categories.
Status as published by the SBTi
Primary SBTi record: 10x Genomics
Carbon3 shows each record exactly as the SBTi publishes it, and does not assess, rate or endorse targets. A validated target says nothing about any market instrument.
Registry records naming the company as beneficiary
No voluntary credit retirements linked to this company
Carbon3 has not found a retirement in the public voluntary carbon market registry data it tracks that names this company as the beneficiary.
The median appears when at least one peer reports all three scopes.
6 of 6 named peers report all three scopes, so their Scope 3 share can be compared.
Cached 18 Aug 2026
10x Genomics has set SBTi-validated targets to cut total GHG emissions 62% by 2030 from a 2019 baseline across Scopes 1-3, reach near-zero Scope 1 and 2 emissions by 2025, and reduce Scope 3 intensity 50% by 2040, matching leading biotech peers on science-based decarbonization. Renewable PPAs with NextEra Energy and PG&E, carbon insetting via regenerative agriculture with First Climate and AAK, circular programs with TerraCycle and Veolia, supplier decarbonization with Thermo Fisher and Illumina, and green logistics with DHL and FedEx will deliver over 51,000 mtCO2e annual reductions while partnerships with the Economic Development Board of Singapore and PSCI strengthen supply-chain resilience. These initiatives, backed by $26.5 million in investments, are forecast to yield $49 million in returns over 4-7 years, $3.5 million yearly carbon credit revenue, and $8 million in efficiency savings, converting carbon insetting from a cost center into a direct revenue stream and economic catalyst that also lifts ESG transparency scores and mitigates regulatory and reputational risks.
This report is generated by AI from public sources and may contain errors, so readers should check the linked sources before relying on it.
10x Genomics has committed to near-term science-based emissions reduction targets through the Science Based Targets initiative (SBTi), with validated goals covering full supply chain.
Validated SBTi target to reduce total GHG emissions by 62% by 2030 versus 2019 baseline, including Scope 1, 2, and 3.
Aims for near-zero emissions in direct operations and purchased energy by 2025.
Target of 50% reduction in Scope 3 emissions intensity across purchased goods, services, and logistics by 2040.
Achieved UN SDG ESG Transparency Score of 4.0 overall, with environmental score of 3.4 and social score of 4.0.
Emerging projects catalog, status as reported by each project
No projects linked to this company yet
Carbon3 has not yet found a public decarbonization project that names this company.
No inset projects are listed for this company yet.
Suppliers to 10x Genomics, Inc. can list a reduction project on Carbon3 at no cost, so that the company could co-fund it.
Sign in with an email address at the company's own domain.
Flag corrections and upload newer disclosures, which Carbon3 checks against a published source.
Turn verified supply-chain reductions into inset credits that partners can co-fund.
A free account also gives access to downloads, alerts and new research reports.